The Globe and Mail reports in its Friday, Aug. 23, edition that Stifel analyst Justin Keywood has reiterated his "buy" recommendation for Medexus Pharmaceuticals. The Globe's David Leeder writes in the Eye On Equities column that Mr. Keywood gave his share target a 50-cent boost to $3.50. Analysts on average target the shares at $3.30. The Stifel stockpicker says in a note: "We increase our target price, predicated on an expected FDA approval of Treosulfan but also increased confidence of a cash flow-positive base business in the near-term. Although there remains regulatory and binary risk in predicting an FDA approval, our greater conviction stems from Medexus reaffirming last week that an FDA response should come by late October, along with TREO already being approved and commercialized in Canada and the UK. The use of FDA consultants is believed to have led to the FDA accepting TREO for essentially a third review and derisks the process, in our view. As we reevaluated our broader pharma coverage, we believe Medexus's valuation has fallen too far at only four times expected EBITDA and highlights a solid risk-to-reward setup, ahead of the October catalysts and leading to our 'buy' view."